Fig. 7: CD5L overexpression is associated with bevacizumab resistance and worse overall survival in ovarian cancer patients.
From: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
A Representative images of CD5L expression measured by immunohistochemical (IHC) analysis in patients considered as bevacizumab responder (n = 25) or non-responder (n = 11) scale bar = 100 µm. Quantification of CD5L expression measured by IHC analysis scaled from 0 (absent) to 10 (high) in bevacizumab responders (n = 25) versus non-responders (n = 11). B CD5L serum protein levels in ovarian cancer patients that were classified as either responsive (n = 8) or non-responsive (n = 7) to bevacizumab. C Representative images of low (upper) and high (lower) CD5L protein expression in tumor endothelial cells from a human ovarian cancer patient cohort; scale bar = 100 µm. D Kaplan–Meier curve of overall survival in patients with high-grade serous ovarian cancer (HGSC) stratified according to CD5L protein expression level (n = 30 for Low and n = 24 for High) as measured by IHC analysis, from a patient cohort in panel (C). The inset on the right shows the curves from 0–80 months only. Data represented as mean values ± SD determined by a two-sided Student t-test was used for statistical calculations, aside from panel (D), which was generated with the use of the log-rank test.
